Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fu Zheng Jie Du Hua Yu in HBV-related HCC
NCT05152498Phase 1Unknown
- Sponsor
- Beijing Ditan Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1 trial of Fuzheng Jiedu Formula in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Time to Progression at 1 year. Status: unknown.
02
Drugs
Fuzheng Jiedu Formula
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05152498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152498.